Evidence map›Paper›PMID 39470201›Full record

ArticleAntimicrobial agents and chemotherapy2024

Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant

Tingting Xu, Weiyuan Wu, Lili Huang, Bin Liu, Qiaodong Zhang, Jingjie Song, Jialong Liu, Bing Li, Zhao Li, Kai Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Optimizing target inactivation to treat multidrug-resistantAntimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Article
  4. Antimicrobial agents and chemotherapy · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tingting Xu *Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.ORCID 0000-0002-2913-2133
Weiyuan Wu *Clinical Laboratory, Second Clinical Medical College (Shenzhen People's Hospital), Jinan University; the First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology, Shenzhen, Guangdong, China.
Lili HuangShenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Bin LiuKey Laboratory of Molecular Microbiology and Technology, Nankai University, Ministry of Education, Tianjin, China.
Qiaodong ZhangShanghai Frontiers Science Center for Drug Target Identification and Delivery, and the Engineering Research Center of Cell and Therapeutic Antibody of the Ministry of Education, School of Pharmaceutical Sciences, National Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, Shanghai, China.
Jingjie SongDepartment of Clinical Laboratory, Fifth Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Jialong LiuShenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Bing LiKey Laboratory of Microorganism Application and Risk Control, Ministry of Ecology and Environment, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, Guangdong, China.
Zhao LiSchool of Basic Medicine Sciences, Guangxi Medical University, Nanning, Guangxi, China.
Kai ZhouShenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.ORCID 0000-0002-7320-291X

Funding

Guangdong Basic and Applied Basic Research Foundation 2024A1515030182Guangxi University Young and Middle-aged Teachers' Basic Research Ability Improvement Project 2023KY0103MOST | National Key Research and Development Program of China (NKPs) 2022YFE0103200,2021YFC2300300MOST | National Natural Science Foundation of China (NSFC) 82172330Shenzhen Science and Technology Program JCYJ20210324113608022
6 · The paper itself

Abstract

The rapid rise of multidrug resistance (MDR) among Gram-negative bacteria has accelerated the development of novel therapies. Ceftazidime-avibactam (CZA) is a novel β-lactam/β-lactamase inhibitor recently approved for the treatment of limited infectious diseases. Here, we describe a novel CMY variant, CMY-192, that confers high-level resistance to CZA. This gene was detected in a clinical MDR

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeDrug CombinationsDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli InfectionsMicrobial Sensitivity TestsPlasmidsAnimalsbeta-LactamasesFemaleHumansMiceUrinary Tract InfectionsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo Compoundsbeta-LactamasesCeftazidimeDrug Combinationsantibiotic resistanceblaCMY-192ceftazidime-avibactamEscherichia coliβ-lactamase

Identifiers

PMID39470201
PMCPMC11619348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.